B. K. BLACKBURN - Concepedia

Author

B. K. BLACKBURN

Also Known As

B Blackburn, B. Blackburn, B. K. BLACKBURN, Brandi Blackburn

Publications

198

Citations

H-Index

Concepts

All Affiliations

B. K. BLACKBURN is an author at Genetic Technologies (Australia) specializing in medicine, pharmacology, and vascular biology.

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	186
2	Biochemistry	2	2	110
3	Natural Sciences	1	1	78
4	Biomolecular Engineering	1	1	78
5	Chemical Biology	1	1	78

B. K. BLACKBURN

Publications

186

Citations

H-Index

Page 1

	Year	Citations
Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Maria Luı́sa Rodrigues, Leonard G. Presta, Claire E. Kotts, PubMed ImmunologyAntimicrobial ChemotherapyCephalosporin Doxorubicin ProdrugChemical BiologySynthetic Immunology	1995	78
Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-κB activation Alastair M. Buchan, H Li, B. K. BLACKBURN Neuroreport ImmunologyCell DeathCerebrovascular DiseaseCerebral Vascular RegulationNeuroinflammation	2000	49
2-SUBSTITUTED PI SYSTEM DERIVATIVES OF ADENOSINE THAT ARE CORONARY VASODILATORS ACTING VIA THE A<sub>2A</sub>ADENOSINE RECEPTOR Jeff Zablocki, Venkata P. Palle, B. K. BLACKBURN, Nucleosides Nucleotides & Nucleic Acids Molecular PharmacologyMolecular PhysiologyBiochemistryCardiovascular DiseaseAdenosine Derivative	2001	32
Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. Canio J. Refino, Nishit B. Modi, Sherron Bullens, PubMed Molecular PharmacologyThrombosisProdrug FormTerminal Half-lifePlatelet Aggregation	1998	27

Page 1